Find here all our blog posts tagged with: clinical trials.

Abstract glowing branching pathways symbolizing decision drift in automated clinical trial monitoring.

Clinical Trials Are Running Agentic AI Faster Than Regulators Can Define It

Agentic AI now handles protocol deviation detection and trial monitoring, but no current framework tests for decision drift across autonomous runs.

Overlapping translucent rings symbolizing intersecting regulatory frameworks over a data network, representing convergence without any visible text.

Agentic AI in Clinical Trials Isn't Exempt From High-Risk Classification

Agentic AI tools for trial design look administrative, but EU AI Act and MDR overlap rules can pull them into conformity assessment regardless of vendor intent.

Glowing digital data particles representing AI-driven drug discovery converge on a stone archway symbolizing regulatory evidence requirements.

AI Discovers Drugs. It Doesn't Approve Them.

AI drug discovery has drawn billions in investment but zero FDA approvals, and the bottleneck sponsors need to plan for is evidence, not speed.

Glowing molecular structures hover above empty hospital gurneys in a dim laboratory, symbolizing the gap between AI-driven discovery and clinical trial execution.

The AI Drug Discovery Boom Is Outrunning Trial Execution

Generative AI is accelerating molecule design, but no AI-discovered drug has cleared trials, and regulators have yet to define how AI governs the trials themselves.

Glowing molecular structures multiplying rapidly on one side and funneling through a narrow glass bottleneck on the other, symbolizing the gap between AI drug discovery and clinical trial execution.

AI Can Design a Drug. It Still Can't Get One Approved.

Generative AI is accelerating drug candidate design, but no AI-discovered molecule has reached approval because clinical trial execution and its regulatory footing remain unresolved.

An empty clinical trial room lit in blue with abstract projected data lines on the wall.

The Trial Floor Is the Next Oversight Line, Not the Device Shelf

FDA's closed RFI on AI-enabled early-phase trials signals a second oversight track distinct from device review, and sponsors are moving faster than either.

A half-built institutional archive of steel shelving and scaffolding lit by a single shaft of light, symbolizing regulatory infrastructure under construction.

FDA Is Assembling the Machinery Before It Finishes the Rule

FDA's device review architecture and new leadership roles point toward trial-side AI scrutiny, though the timeline and scope remain genuinely unsettled.

Rows of archived clinical trial samples in cold storage, with one vial illuminated as if being re-examined by new analysis.

The Next Regulatory Question Isn't the Model. It's the Data It Rescued.

AI-driven reanalysis of failed clinical trials is producing new evidence outside the systems built to validate it, and GxP quality frameworks have not caught up.

Abstract clinical trial operations center with streams of light connecting monitoring stations, symbolizing ungoverned AI coordination across trial execution.

The Clinical Trial Has No AI Rulebook

Sponsors are deploying AI across trial execution with no dedicated regulatory framework, leaving GCP and data integrity obligations to fill the gap alone.

A researcher examines a molecular model in a lab with abstract data visualizations glowing in the background.

FDA's Other AI Track: Drug Development Gets Its Own Playbook

While FDA's device guidance draws attention, a parallel track for AI in early-phase clinical trials and drug development is quietly taking shape.

A human silhouette made of light particles dissolving between physical form and abstract data streams in a clinical setting.

Simulation-Guided Trials Are Ahead of the Law

Digital twins and virtual control arms are entering pivotal trial design faster than GDPR and MDR frameworks can validate the data behind them.

A lone analyst reviews holographic trial data in an otherwise empty clinical monitoring room lit in blue light.

The Governance Gap in Clinical Trial Operations AI

Agentic AI is spreading through trial enrollment, monitoring, and feasibility work faster than FDA, EU AI Act, or ISO 42001 pathways built for medical devices can reach it.